S B Cohen

Summary

Publications

  1. pmc A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate
    S B Cohen
    Department of Rheumatology, St Paul Medical Center, Dallas, Texas 75235, USA
    Ann Rheum Dis 63:1062-8. 2004
  2. ncbi request reprint Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy
    S B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Rheumatology (Oxford) 43:704-11. 2004
  3. ncbi request reprint Bringing the clinical experience with anakinra to the patient
    S B Cohen
    St Paul University Medical Center, Dallas, Texas, USA
    Rheumatology (Oxford) 42:ii36-40. 2003
  4. ncbi request reprint Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial
    R M Fleischmann
    Radiant Research Dallas, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX 75235, USA
    Curr Med Res Opin 21:1181-90. 2005
  5. ncbi request reprint Leflunomide
    S B Cohen
    St Paul University Medical Center, Dallas, Texas, USA
    Int J Clin Pract 57:115-20. 2003
  6. ncbi request reprint Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial
    P Garnero
    INSERM Research Unit 664, Lyon, France
    Osteoarthritis Cartilage 16:660-6. 2008
  7. doi request reprint Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel
    D E Furst
    Geffen School of Medicine, University of California at Los Angeles, 1000 Veteran Ave Rm 32 59, Los Angeles, CA 90095 1670, USA
    Rheumatology (Oxford) 47:194-9. 2008

Detail Information

Publications7

  1. pmc A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate
    S B Cohen
    Department of Rheumatology, St Paul Medical Center, Dallas, Texas 75235, USA
    Ann Rheum Dis 63:1062-8. 2004
    ..To assess the efficacy and safety of 100 mg daily anakinra (Kineret), a recombinant form of the naturally occurring interleukin 1 receptor antagonist, plus methotrexate (MTX) in reducing the signs and symptoms of rheumatoid arthritis (RA)...
  2. ncbi request reprint Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy
    S B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Rheumatology (Oxford) 43:704-11. 2004
    ..To determine whether patient-reported outcomes may differentiate treatment response better than physician-reported outcomes for rheumatoid arthritis (RA) patients being treated with anakinra...
  3. ncbi request reprint Bringing the clinical experience with anakinra to the patient
    S B Cohen
    St Paul University Medical Center, Dallas, Texas, USA
    Rheumatology (Oxford) 42:ii36-40. 2003
    ....
  4. ncbi request reprint Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial
    R M Fleischmann
    Radiant Research Dallas, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX 75235, USA
    Curr Med Res Opin 21:1181-90. 2005
    ..We evaluated the ability of patients receiving infliximab plus MTX to achieve and maintain a clinical response while the dose of MTX was tapered...
  5. ncbi request reprint Leflunomide
    S B Cohen
    St Paul University Medical Center, Dallas, Texas, USA
    Int J Clin Pract 57:115-20. 2003
    ..This report will focus on the use of leflunomide in rheumatoid arthritis based on the data from these trials as well information on the efficacy and safety learned from post release clinical experience...
  6. ncbi request reprint Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial
    P Garnero
    INSERM Research Unit 664, Lyon, France
    Osteoarthritis Cartilage 16:660-6. 2008
    ....
  7. doi request reprint Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel
    D E Furst
    Geffen School of Medicine, University of California at Los Angeles, 1000 Veteran Ave Rm 32 59, Los Angeles, CA 90095 1670, USA
    Rheumatology (Oxford) 47:194-9. 2008
    ..A panel of rheumatologists was convened to develop guidelines to assess adequacy of disease control, focusing on the use of disease-modifying anti-rheumatic drugs...